Executive Summary: Bridging the Gap in Breast Cancer Treatment
The landscape of breast cancer research is at a critical juncture. While advancements in targeted therapies, immunotherapies, and precision medicine have significantly improved survival rates, the clinical challenge of therapeutic resistance remains a formidable barrier to long-term remission. To address this, Taylor & Francis has officially announced an open call for submissions for a specialized Article Collection in the peer-reviewed journal Breast Cancer: Targets and Therapy.
Titled "Breast cancer under therapeutic pressure: Adaptive states, resistance and emerging vulnerabilities," this initiative seeks to aggregate high-impact research that moves beyond mere observation. The collection aims to investigate the complex biological mechanisms that allow breast cancer cells to evolve, persist, and recur under the selective pressure of modern medical interventions. With a submission deadline of July 1, 2027, the project represents a multi-year effort to synthesize the latest breakthroughs in basic, translational, and clinical oncology.
The Core Challenge: Understanding Adaptive Resistance
Breast cancer is not a static disease; it is a highly plastic, evolving entity. When subjected to systemic therapies—whether endocrine, chemotherapy, or targeted molecular inhibitors—tumor cells often undergo "adaptive reprogramming." This process allows sub-populations of cells to survive, eventually leading to tumor recurrence or metastatic progression.
The upcoming Article Collection is designed to dissect these adaptive states. The organizers are specifically looking for contributions that delineate how treatment-induced biological changes influence:
- Therapeutic Response: The immediate molecular shifts occurring within the tumor microenvironment.
- Resistance Mechanisms: The genetic and epigenetic pathways that confer survival advantages to cancer cells.
- Recurrence Patterns: How dormant or resistant cell populations re-emerge to drive late-stage disease.
- Emerging Vulnerabilities: New therapeutic targets revealed precisely by the changes cancer cells undergo during treatment.
By focusing on these areas, the journal aims to provide a platform for research that provides actionable insights, bridging the gap between bench-side laboratory discovery and bedside patient care.
Chronology of the Initiative
The call for papers follows a period of rapid development in the field of breast cancer genomics. The following timeline outlines the trajectory of this initiative and the expectations for the coming years:
- Q3 2024 (Announcement): Taylor & Francis formally announces the Article Collection, establishing the scope and inviting the global oncology community to participate.
- 2025–2026 (Development Phase): Researchers are encouraged to conduct longitudinal studies and deep-dive analyses into therapeutic resistance, utilizing emerging single-cell sequencing and spatial transcriptomics technologies.
- July 1, 2027 (Submission Deadline): The final cutoff for manuscript submissions. This long lead time reflects the complexity of the research required, allowing for multi-year clinical trials or comprehensive translational studies to reach completion.
- 2027–2028 (Peer Review and Publication): Following the deadline, the journal will initiate its rigorous, double-blind peer-review process to ensure all published data meet the highest standards of scientific integrity.
Supporting Data: The Clinical Necessity
The impetus for this collection is supported by current epidemiological and clinical data. Despite advancements, breast cancer remains one of the most common malignancies globally. Data from major cancer research centers consistently highlight that while primary tumors often respond well to frontline therapies, the subset of patients who develop resistance to second- and third-line therapies face significantly poorer prognoses.
Recent studies have shown that tumor heterogeneity is a primary driver of this resistance. As therapy eliminates sensitive cell populations, it inadvertently selects for resistant clones. Current research suggests that the "therapeutic pressure" applied by drugs like CDK4/6 inhibitors or anti-HER2 therapies can trigger cellular stress responses, such as autophagy or metabolic shifts, which the tumor uses as a survival mechanism. This Article Collection is specifically targeted at identifying the "molecular toggles" that control these shifts, potentially enabling the development of combination therapies that "lock" the cancer in a sensitive state.
Official Guidelines and Editorial Standards
To ensure the quality and impact of the collection, Taylor & Francis has instituted specific editorial requirements for all prospective contributors:
Submission Expectations
- Beyond Descriptive Research: The editorial board emphasizes that they are not looking for simple descriptive associations. Manuscripts must provide a clear mechanism of action. The authors must explain how a specific biological change facilitates resistance or creates a new vulnerability.
- Article Types: The collection welcomes Original Research and Review Articles. Additionally, the editors are inviting expert opinions and commentaries that propose new conceptual frameworks for understanding cancer evolution.
- Rigorous Peer Review: All submissions will undergo the standard, full peer-review process associated with Breast Cancer: Targets and Therapy. To maintain impartiality, the Guest Advisor for the collection will not handle manuscripts unless they are an active member of the Editorial Board, ensuring that the selection process remains entirely objective.
Practical Information for Authors
Before drafting, authors are required to consult the journal’s official scope and follow the author submission instructions.
For any inquiries, including requests for discount codes for open access fees, interested parties are directed to contact Rebecca Turner at the designated editorial email address. When submitting, authors must ensure they select the correct "Article Collection" category from the journal’s submission portal drop-down menu to ensure their work is routed correctly.
Implications for Future Oncology
The broader implication of this call for research is a shift toward "adaptive therapy." Instead of focusing solely on the maximum tolerated dose of a single drug, modern oncology is moving toward managing the tumor as a dynamic system. By understanding the adaptive states induced by current standard-of-care treatments, researchers hope to design "evolutionary" treatment schedules—schedules that anticipate the cancer’s move and neutralize it before it can manifest as clinical resistance.
Impact on Patient Care
For clinicians, the insights gathered in this collection could eventually lead to:
- Predictive Biomarkers: Identifying which patients are likely to develop specific resistance patterns before they undergo treatment.
- Sequential Therapy Optimization: Determining the ideal order and combination of drugs to suppress the emergence of resistant clones.
- Novel Drug Development: Identifying "synthetic lethal" relationships where the very mechanism the cancer uses to survive therapy simultaneously creates an Achilles’ heel that a second drug can exploit.
Conclusion: A Call to Action
The challenge of therapeutic resistance is the next great frontier in breast cancer treatment. By consolidating the latest findings into a single, high-visibility collection, Taylor & Francis is providing a vital resource for the global oncology community.
Researchers working at the intersection of molecular biology, pharmacology, and clinical oncology are encouraged to leverage this opportunity to contribute to a body of work that could redefine standard practices in the coming decade. Whether through the exploration of tumor cell plasticity, the role of the microenvironment in drug sequestration, or the impact of metabolic reprogramming, the contributions to this collection will play a pivotal role in shifting the narrative from disease management to long-term, sustainable control.
As the 2027 deadline approaches, the scientific community looks forward to the insights that will undoubtedly emerge from this collaboration. For those at the forefront of breast cancer research, this is more than just a call for papers—it is a call to solve one of the most pressing puzzles in human health.
For more information on the "Breast cancer under therapeutic pressure: Adaptive states, resistance and emerging vulnerabilities" collection, please visit the official Taylor & Francis submission portal.
About the Author
